Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Repertoire Sequencing of B Cells Elucidates the Role of UNG and Mismatch Repair Proteins in Somatic Hypermutation in Humans.

IJspeert H, van Schouwenburg PA, Pico-Knijnenburg I, Loeffen J, Brugieres L, Driessen GJ, Blattmann C, Suerink M, Januszkiewicz-Lewandowska D, Azizi AA, Seidel MG, Jacobs H, van der Burg M.

Front Immunol. 2019 Aug 27;10:1913. doi: 10.3389/fimmu.2019.01913. eCollection 2019.

2.

Identification of CVID Patients With Defects in Immune Repertoire Formation or Specification.

van Schouwenburg PA, IJspeert H, Pico-Knijnenburg I, Dalm VASH, van Hagen PM, van Zessen D, Stubbs AP, Patel SY, van der Burg M.

Front Immunol. 2018 Nov 23;9:2545. doi: 10.3389/fimmu.2018.02545. eCollection 2018.

3.

A kindred with mutant IKAROS and autoimmunity.

Van Nieuwenhove E, Garcia-Perez JE, Helsen C, Rodriguez PD, van Schouwenburg PA, Dooley J, Schlenner S, van der Burg M, Verhoeyen E, Gijsbers R, Frietze S, Schjerven H, Meyts I, Claessens F, Humblet-Baron S, Wouters C, Liston A.

J Allergy Clin Immunol. 2018 Aug;142(2):699-702.e12. doi: 10.1016/j.jaci.2018.04.008. Epub 2018 Apr 27. No abstract available.

4.

Antigen Receptor Galaxy: A User-Friendly, Web-Based Tool for Analysis and Visualization of T and B Cell Receptor Repertoire Data.

IJspeert H, van Schouwenburg PA, van Zessen D, Pico-Knijnenburg I, Stubbs AP, van der Burg M.

J Immunol. 2017 May 15;198(10):4156-4165. doi: 10.4049/jimmunol.1601921. Epub 2017 Apr 17.

5.

Genetic defects in PI3Kδ affect B-cell differentiation and maturation leading to hypogammaglobulineamia and recurrent infections.

Wentink M, Dalm V, Lankester AC, van Schouwenburg PA, Schölvinck L, Kalina T, Zachova R, Sediva A, Lambeck A, Pico-Knijnenburg I, van Dongen JJ, Pac M, Bernatowska E, van Hagen M, Driessen G, van der Burg M.

Clin Immunol. 2017 Mar;176:77-86. doi: 10.1016/j.clim.2017.01.004. Epub 2017 Jan 17.

PMID:
28104464
6.

Evaluation of the Antigen-Experienced B-Cell Receptor Repertoire in Healthy Children and Adults.

IJspeert H, van Schouwenburg PA, van Zessen D, Pico-Knijnenburg I, Driessen GJ, Stubbs AP, van der Burg M.

Front Immunol. 2016 Oct 17;7:410. eCollection 2016.

7.

Neutralizing capacity of monoclonal and polyclonal anti-natalizumab antibodies: The immune response to antibody therapeutics preferentially targets the antigen-binding site.

van Schie KA, Kruithof S, van Schouwenburg PA, Vennegoor A, Killestein J, Wolbink G, Rispens T.

J Allergy Clin Immunol. 2017 Mar;139(3):1035-1037.e6. doi: 10.1016/j.jaci.2016.09.014. Epub 2016 Oct 4. No abstract available.

PMID:
27717666
8.

Using monoclonal antibodies as an international standard for the measurement of anti-adalimumab antibodies.

van Schouwenburg PA, Kruithof S, Wolbink G, Wouters D, Rispens T.

J Pharm Biomed Anal. 2016 Feb 20;120:198-201. doi: 10.1016/j.jpba.2015.12.040. Epub 2015 Dec 28.

PMID:
26748377
9.

Hypomorphic function and somatic reversion of DOCK8 cause combined immunodeficiency without hyper-IgE.

Kienzler AK, van Schouwenburg PA, Taylor J, Marwah I, Sharma RU, Noakes C, Thomson K, Sadler R, Segal S, Ferry B, Taylor JC, Blair E, Chapel H, Patel SY.

Clin Immunol. 2016 Feb;163:17-21. doi: 10.1016/j.clim.2015.12.003. Epub 2015 Dec 8.

10.

Chronic mucocutaneous candidiasis: characterization of a family with STAT-1 gain-of-function and development of an ex-vivo assay for Th17 deficiency of diagnostic utility.

Dhalla F, Fox H, Davenport EE, Sadler R, Anzilotti C, van Schouwenburg PA, Ferry B, Chapel H, Knight JC, Patel SY.

Clin Exp Immunol. 2016 May;184(2):216-27. doi: 10.1111/cei.12746. Epub 2016 Feb 9.

11.

Application of whole genome and RNA sequencing to investigate the genomic landscape of common variable immunodeficiency disorders.

van Schouwenburg PA, Davenport EE, Kienzler AK, Marwah I, Wright B, Lucas M, Malinauskas T, Martin HC; WGS500 Consortium, Lockstone HE, Cazier JB, Chapel HM, Knight JC, Patel SY.

Clin Immunol. 2015 Oct;160(2):301-14. doi: 10.1016/j.clim.2015.05.020. Epub 2015 Jun 26.

12.

Factors influencing success of clinical genome sequencing across a broad spectrum of disorders.

Taylor JC, Martin HC, Lise S, Broxholme J, Cazier JB, Rimmer A, Kanapin A, Lunter G, Fiddy S, Allan C, Aricescu AR, Attar M, Babbs C, Becq J, Beeson D, Bento C, Bignell P, Blair E, Buckle VJ, Bull K, Cais O, Cario H, Chapel H, Copley RR, Cornall R, Craft J, Dahan K, Davenport EE, Dendrou C, Devuyst O, Fenwick AL, Flint J, Fugger L, Gilbert RD, Goriely A, Green A, Greger IH, Grocock R, Gruszczyk AV, Hastings R, Hatton E, Higgs D, Hill A, Holmes C, Howard M, Hughes L, Humburg P, Johnson D, Karpe F, Kingsbury Z, Kini U, Knight JC, Krohn J, Lamble S, Langman C, Lonie L, Luck J, McCarthy D, McGowan SJ, McMullin MF, Miller KA, Murray L, Németh AH, Nesbit MA, Nutt D, Ormondroyd E, Oturai AB, Pagnamenta A, Patel SY, Percy M, Petousi N, Piazza P, Piret SE, Polanco-Echeverry G, Popitsch N, Powrie F, Pugh C, Quek L, Robbins PA, Robson K, Russo A, Sahgal N, van Schouwenburg PA, Schuh A, Silverman E, Simmons A, Sørensen PS, Sweeney E, Taylor J, Thakker RV, Tomlinson I, Trebes A, Twigg SR, Uhlig HH, Vyas P, Vyse T, Wall SA, Watkins H, Whyte MP, Witty L, Wright B, Yau C, Buck D, Humphray S, Ratcliffe PJ, Bell JI, Wilkie AO, Bentley D, Donnelly P, McVean G.

Nat Genet. 2015 Jul;47(7):717-726. doi: 10.1038/ng.3304. Epub 2015 May 18.

13.

Functional analysis of the anti-adalimumab response using patient-derived monoclonal antibodies.

van Schouwenburg PA, Kruithof S, Votsmeier C, van Schie K, Hart MH, de Jong RN, van Buren EE, van Ham M, Aarden L, Wolbink G, Wouters D, Rispens T.

J Biol Chem. 2014 Dec 12;289(50):34482-8. doi: 10.1074/jbc.M114.615500. Epub 2014 Oct 17. Review.

14.

Nanomolar to sub-picomolar affinity measurements of antibody-antigen interactions and protein multimerizations: fluorescence-assisted high-performance liquid chromatography.

Rispens T, Ooijevaar-de Heer P, Derksen NI, Wolbink G, van Schouwenburg PA, Kruithof S, Aalberse RC.

Anal Biochem. 2013 Jun 15;437(2):118-22. doi: 10.1016/j.ab.2013.02.027. Epub 2013 Mar 13.

PMID:
23499975
15.

Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis.

van Schouwenburg PA, Rispens T, Wolbink GJ.

Nat Rev Rheumatol. 2013 Mar;9(3):164-72. doi: 10.1038/nrrheum.2013.4. Epub 2013 Feb 12. Review.

PMID:
23399692
16.

Long-term measurement of anti-adalimumab using pH-shift-anti-idiotype antigen binding test shows predictive value and transient antibody formation.

van Schouwenburg PA, Krieckaert CL, Rispens T, Aarden L, Wolbink GJ, Wouters D.

Ann Rheum Dis. 2013 Oct;72(10):1680-6. doi: 10.1136/annrheumdis-2012-202407. Epub 2013 Jan 7.

PMID:
23300118
17.

Monoclonal anti-citrullinated protein antibodies selected on citrullinated fibrinogen have distinct targets with different cross-reactivity patterns.

van de Stadt LA, van Schouwenburg PA, Bryde S, Kruithof S, van Schaardenburg D, Hamann D, Wolbink G, Rispens T.

Rheumatology (Oxford). 2013 Apr;52(4):631-5. doi: 10.1093/rheumatology/kes371. Epub 2012 Dec 22.

PMID:
23264551
18.

Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation.

van Schouwenburg PA, van de Stadt LA, de Jong RN, van Buren EE, Kruithof S, de Groot E, Hart M, van Ham SM, Rispens T, Aarden L, Wolbink GJ, Wouters D.

Ann Rheum Dis. 2013 Jan;72(1):104-9. doi: 10.1136/annrheumdis-2012-201445. Epub 2012 Jul 3.

PMID:
22759910
19.

IgG4 production against adalimumab during long term treatment of RA patients.

van Schouwenburg PA, Krieckaert CL, Nurmohamed M, Hart M, Rispens T, Aarden L, Wouters D, Wolbink GJ.

J Clin Immunol. 2012 Oct;32(5):1000-6. doi: 10.1007/s10875-012-9705-0. Epub 2012 May 24.

PMID:
22622790
20.

Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up.

Bartelds GM, Krieckaert CL, Nurmohamed MT, van Schouwenburg PA, Lems WF, Twisk JW, Dijkmans BA, Aarden L, Wolbink GJ.

JAMA. 2011 Apr 13;305(14):1460-8. doi: 10.1001/jama.2011.406.

PMID:
21486979
21.

The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept.

Jamnitski A, Bartelds GM, Nurmohamed MT, van Schouwenburg PA, van Schaardenburg D, Stapel SO, Dijkmans BA, Aarden L, Wolbink GJ.

Ann Rheum Dis. 2011 Feb;70(2):284-8. doi: 10.1136/ard.2010.135111. Epub 2010 Nov 10.

PMID:
21068090
22.

A novel method for the detection of antibodies to adalimumab in the presence of drug reveals "hidden" immunogenicity in rheumatoid arthritis patients.

van Schouwenburg PA, Bartelds GM, Hart MH, Aarden L, Wolbink GJ, Wouters D.

J Immunol Methods. 2010 Oct 31;362(1-2):82-8. doi: 10.1016/j.jim.2010.09.005. Epub 2010 Sep 9.

PMID:
20833178

Supplemental Content

Loading ...
Support Center